ArticleNature2024
Complete biosynthesis of QS-21 in engineered yeast.
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed.
- Functional characterization of four glycosyltransferases for biosynthesis of steroidal saponins in medicinal plantSynthetic and systems biotechnology · 2026Article
- Advances in large DNA fragment assembly for microbial cell factory engineering.Quantitative biology (Beijing, China) · 2026Review
- Nitrene generation and transfer for unnatural biosynthesis in living cells.Nature chemistry · 2026Article
- Cinchona alkaloid scaffold decoded.Plant communications · 2026Article
- A yeast-based platform for etoposide production via yatein bioconversion.Metabolic engineering communications · 2026Article
- Advances in the heterologous biosynthesis of QS saponins: a review.Microbial cell factories · 2026Review
- How Cinchona builds quinine.Nature chemical biology · 2026Article
- MechFind: a computational framework for de novo prediction of enzyme mechanisms.Nature communications · 2026Article
- Toward sustainable food preservatives: high-level production of sorbic acid in engineered Saccharomyces cerevisiae.Nature communications · 2026Article
- Multi-omics and functional analyses in Aesculus wilsonii elucidate the biosynthetic pathways of moretane- and oleanane-type triterpenoids.Plant communications · 2026Article
- Article
- Biomanufacturing of Natural Bioactive Compounds.Molecules (Basel, Switzerland) · 2026Article
- Telomere-to-telomere genome assembly and multiomics analyses illustrate the high accumulation of quercetin glucosides in tetraploidHorticulture research · 2026Article
- The Cinderella tree,Plants, people, planet · 2026Article
- Biodegradable Polymers for Application as Robust Immunomodulatory Biomaterial Carrier Systems.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Advances in artificial biosynthesis of bioactive plant natural products.Current opinion in biotechnology · 2026Review
- Advances in Adjuvanted Rabies Vaccines.Vaccines · 2026Review
- Engineering Saccharomyces cerevisiae to improve heterologous abscisic acid production.Microbial cell factories · 2026Article
- Improved de novo production of prostaglandin FCommunications biology · 2026Article
- Polyphyllin II Triggers Pyroptosis in Hepatocellular Carcinoma via Modulation of the ROS/NLRP3/Caspase-1/GSDMD Axis.Antioxidants (Basel, Switzerland) · 2026Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
QS-21 is a potent vaccine adjuvant and remains the only saponin-based adjuvant that has been clinically approved for use in humans
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.